MeiraGTx Holdings (MGTX) Fundamentals 2026 — Revenue Analysis | SniperIQ
MeiraGTx Holdings (MGTX) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is MeiraGTx Holdings's market cap?
MeiraGTx Holdings (MGTX) has a market capitalization of approximately
How profitable is MeiraGTx Holdings?
MeiraGTx Holdings runs a net profit margin of -151.1%, a gross margin of 91.6%, and an operating margin of -131.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does MeiraGTx Holdings generate?
MeiraGTx Holdings reported revenue of $81M for fiscal year 2025, with net income of -
Does MeiraGTx Holdings pay a dividend?
MeiraGTx Holdings does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is MeiraGTx Holdings financially healthy?
MeiraGTx Holdings carries a debt-to-equity ratio of -1.51x and a current ratio of 0.55x, with a market beta of 1.21. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is MeiraGTx Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For MeiraGTx Holdings (MGTX) the key facts are: market cap
Track MeiraGTx Holdings's full fundamentals live
Get MeiraGTx Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.